### PATENT APPLICATION DOCKET NO.: 0725.1039-009

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Marc W. Kirschner and Noriyuki Kinoshita

Continuation Application of

Application No.:

09/507,773

February 18, 2000

Group Art Unit:

Examiner:

Not yet assigned

Not yet assigned

For:

Filed:

ISOLATED FGF RECEPTOR

Date: 10:00 16, 2001

EXPRESS MAIL LABEL NO. EV 005369434 US

## INFORMATION DISCLOSURE STATEMENT

Washington, D.C. 20231 Sir

**Assistant Commissioner for Patents** 

311. This II	nformation Disclosure Statement is submitted:
[ ]	under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)
[ X ]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the mcrits in a non-provisional application, including a CPA, or a Request for Continued Examination).
[]	under 37 CFR 1.97(c) together with either:  [ ] a Statement under 37 CFR 1.97(e), as checked below, or  [ ] a \$180.00 fee under 37 CFR 1.17(p), or  (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
[]	under 37 CFR 1.97(d) together with:  [ ] a Statement under 37 CFR 1.97(e), as checked below, and  [ ] a \$180.00 fee under 37 CFR 1.17(p), or  (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
[ ]	under 37 CFR 1.97(i): Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper. (Filed after payment of issue fee)

Staten	nent Und	ler 37 CFR 1.97(e)					
[ ]	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or						
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.						
Staten	nent Und	der 37 CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000					
[ ]	commi was no	tem of information contained in the Information Disclosure Statement was cited in a unication from a foreign patent office in a counterpart application and this communication at received by any individual designated in § 1.56(c) more than thirty days prior to the of the Information Disclosure Statement.					
[ X ]	Enclosed herewith is form PTO-1449:						
	[]	Copies of the cited references are enclosed.					
	[ X ]	Copies of cited references are enclosed except those entered in prior application, U.S. Serial No. 08/776,207, to which priority under 35 U.S.C. 120 is claimed. The earlier application contains copies of the cited references. (No copies of references are enclosed.)					
	[ ]	The listed references were cited in the enclosed International Search Report in a counterpart foreign application.					
	[]	The "concise explanation" requirement (non-English references) for reference(s) [ under 37 CFR 1.98(a)(3) is satisfied by:					
		[ ] the explanation provided on the attached sheet.					
		[ ] the explanation provided in the Specification.					
		[ ] submission of the enclosed International Search Report.					
		[ ] the enclosed English language abstract.					

[ ]	Applicant requests that the following non-published pending applications be considered:						
Examiner's Initials							
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]			
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]			
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]			
		Examiner	Date	-			
	[ ]	A copy of each above-cited app	olication, including the curre	nt claims, is enclosed.			
	A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.						
The E	xamine nces we	r is requested to return a copy of re considered with the next offic	the above list of pending ap e communication.	plications indicating which			
It is re	equestec	I that the information disclosed h	erein be made of record in the	his application.			
Metho	od of pa	yment:					
[ ]	A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.						
[ ]	Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.						
[X]	Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.						
	Respectfully submitted,						
		I	HAMILTON, BROOK, SMI	TH & REYNOLDS, P.C.			
		]	Antoinette G. Giugliano Registration No.: 42,582 Telephone: (978) 341-0036 Facsimile: (978) 341-0136	Linghau			

Concord, MA 01742-9133
Dated: December 10, 2001

	,.,	A (1. anage)							
PTO 1449 REPRODUCED  INFORMATION DISCLOSURE CITATION IN AN APPLICATION				ATTORNEY DOCKET NO. 0725.1039-009	APPLICAT Contin	uation	of O		
				APPLICANT					
December 10, 2001			Marc W. Kirschner et al.			S. 154			
	(Use	several sheets if nece	ssary)	FILING DATE	GROUP		40 U	2/1/2	
			U.S.	PATENT DOCUMENTS			310		
EXAM INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING IF APPROP	7	
	AA	5,256,643	10-26-93	Persico et al.	514	12	5-29-	90	
	AB	5,264,557	11-23-93	Salomon et al.	530	399	08-23	3-91	
	AC	5,238,916	08-24-93	Goldfarb et al.	514	2	05-27	05-27-88	
	AD								
	1	L	FOREIG	N PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSL YES	NO1TA ON	
	AL	89/04832	01-06-89	WO					
	AM	93/19096	30-09-93	WO					
	AN	2223495A	11-04-90	GB					
-	AO	04036184	06-02-92	JP (English Abstract)				Х	
	AP	92/13948	20-08-92	WO (English Abstract)				X	
	AQ	94/13796	23-06-94	WO				<u> </u>	
		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertinen	t Pages,	Etc.)	····		
	AR	Hanks, S. K., Structural Bio	"Eukaryoti ology, 1:36	C Protein Kinases," 59-383 (1991).	Curren	t Opini	on in		
	AS	Fett, J. W., et al., "Isolation and Characterization of Angiogenin, an Angiogenic Protein from Human Carcinoma Cells," Biochemistry, 24(20):5480-5486 (1985).							
	AT	Maes, P., et al., "The Complete Amino Acid Sequence of Bovine Milk Angiogenin," FEBS Letters, 241(1,2):41-45 (1988).							
	AU	Wilson, R., et al., "2.2 Mb of Contiguous Nucleotide Sequence from Chromosome III of C. elegans," Nature, 368:32-38 (1994).							
	AV	Hao, Q. L., et al., "Isolation and Sequence Analysis of a Novel Human Tyrosine Kinase Gene," Molecular and Cellular Biology, 9(4):1587-1593 (1989).							
	AW	Johnson, D. E., et al., "Diverse Forms of a Receptor for Acidic and Basic Fibroblast Growth Factors," Molecular and Cellular Biology, 10:4728-4736 (1990).							
EXAM	INER	-L		DATE CONSIDERED					

	<u> </u>							
PTO 1449 REPRODUCED  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  December 10, 2001				ATTORNEY DOCKET NO. 0725.1039-009	APPLICATION NO. Continuation of 09/507,773			
				APPLICANT Marc W. Kirschner et al.				
	(Use	several sheets if nece	essary)	FILING DATE	GROUP			
			U.S.	PATENT DOCUMENTS				
EXAM INER INI TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DA IF APPROPRIA	
		<del></del>	FOREIG	GN PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATI YES	NO ON
		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertinen	it Pages,	Etc.)		
	AX	Haugg and Schein Ribonucleases De Nucleic Acids Re	etermined w	Sequences of the Huma with the Polymerase Cha 0(3):612 (1992).	n and Hain Reac	amster tion (P	Secretor	У
	AY	Ciccodicola, A., et al., "Molecular Characterization of a Gene of the 'EGF Family' Expressed in Undifferentiated Human NTERA2 Teratocarcinoma Cells," The EMBO Journal, 8(7):1987-1991 (1989).						
	A2	Dono, R., et al., "The Murine Cripto Gene: Expression During Mesoderm Induction and Early Heart Morphogenesis," Development, 118:1157-1168 (1993).						
	AR2	Basilico and Moscatelli, "The FGF Family of Growth Factors and Oncogenes," Adv. Cancer Res., 59:115-165 (1992).						
	AS2	Developmentally	Expressed	rification and Cloning Ligand for the Mek 4 a 79:157-168 (1994).			r 	
	AT2	Flanagan and Leder, "The <i>kit</i> Ligand: A Cell Surface Molecule Altered in Steel Mutant Fibroblasts," <i>Cell</i> , <i>63</i> :185-194 (1990).						
	AU2	Carlson, M., et al., "The Secreted Form of Invertase in Saccharomyces cerevisiae Is Synthesized from mRNA Encoding a Signal Sequence,"  Molecular and Cellular Biology, 3(3):439-447 (1983).						
	AV2	Musci, T. J., et al., "Regulation of the Fibroblast Growth Factor Receptor in Early Xenopus Embryos," Proc. Natl. Acad Sci. USA, 87:8365-8369 (1990).						
	AW2	Elledge, S. J., et al., "λYES: A Multifunctional cDNA Expression Vector for the Isolation of Genes by Complementation of Yeast and Escherichia coli Mutations," Proc. Natl. Acad. Sci. USA, 88:1731-1735 (1991).						
	AX2	Phosphotyrosine	Antibody S	vel Tyrosine Kinase Ide Screening of cDNA Libra 541-5544, (1988)	ntified ries,"	by Molecul	ar and	
EXAMI	NER			DATE CONSIDERED				

Sheet 3 of 3 PTO 1449 REPRODUCED ATTORNEY DOCKET NO. APPLICATION NO. 0725.1039-009 Continuation of INFORMATION DISCLOSURE CITATION 09/507,773 IN AN APPLICATION APPLICANT Marc W. Kirschner et al. December 10, 2001 (Use several sheets if necessary) FILING DATE GROUP OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) AY2 Amaya, E., et al., "Expression of a Dominant Negative Mutant of the FGF Receptor Disrupts Mesoderm Formation in Xenopus Embryos," Cell, 66:257-270 (1991). Gallwitz, D., et al., "The Actin Gene in Yeast Saccharomyces Cerevisiae: 5' and 3' End Mapping, Flanking and Putative Regulatory Sequences," Nucleic Acids Research, 9:6339-6350 (1981). Kimelman, D., et al., "The Presence of Fibroblast Growth Factor in the Frog Egg: Its Role as a Natural Mesoderm Inducer," Science, 242:1053-1056 (1988). AS3 Isaacs, H.V., et al., "Expression of a Novel FGF in the Xenopus Embryo. A New Candidate Inducing Factor for Mesoderm Formation and Anteroposterior Specification, " Development, 114:711-720 (1992). Tannahill, D., et al., "Developmental Expression of the Xenopus int-2 (FGF-3) Gene: Activation by Mesodermal and Neural Induction," Development, 115:695-702 (1992). Joseph, L. J., et al., "Complete Nucleotide and Deduced Amino Acid Sequences of Human and Murine Preprocathepsin L. An Abundant Transcript Induced by Transformation of Fibroblasts," J. Clin. Invest., 81:1621-1629 (1988). AV3 Gal and Gottesman, "Isolation and Sequence of a cDNA for Human Pro-(Cathepsin L), " Biochem. J., 253:303-306 (1988). Kay, B. K., et al., "Potential for Two Isoforms of the Al Ribonucleoprotein in Xenopus laevis, " Proc. Natl. Acad. Sci. USA, 87:1367-1371 (1990). Kim and Baker, "Isolation of RRM-Type RNA-Binding Protein Genes and the Analysis of Their Relatedness by Using a Numerical Approach," Molecular and Cellular Biology, 13(1):174-183 (1993). AY3 Nieuwkoop and Faber (editors), "The Further Development of the Intestinal Tract and Glands," "External and Internal Stage Criteria in the Development of Xenopus Laevis," Normal Table of Xenopus Laevis (Daudin), pp. 160-170, North-Holland Publishing Company, Amsterdam (1956).Lyons and Nelson, "An Immunological Method for Detecting Gene Expression in Yeast Colonies, " Proc. Natl. Acad. Sci USA, 81:7426-7430

EXAMINER

(1984)

DATE CONSIDERED